CH629219A5 - Verfahren zur herstellung von neuen anthracyclinglycosid-derivaten. - Google Patents

Verfahren zur herstellung von neuen anthracyclinglycosid-derivaten. Download PDF

Info

Publication number: CH629219A5
Authority: CH; Switzerland
Prior art keywords: metal; doxorubicin; anthracycline; glycoside; ferridoxorubicin
Prior art date: 1976-01-16

Application number

CH48477A

Other languages

German (de)

English (en)

Inventor

Mario Dr Gosalvez

Original Assignee

Gosalvez Mario

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1976-01-16

Filing date

1977-01-14

Publication date

1982-04-15

1977-01-14 Application filed by Gosalvez Mario filed Critical Gosalvez Mario

1982-04-15 Publication of CH629219A5 publication Critical patent/CH629219A5/de

Links

229940045799 anthracyclines and related substance Drugs 0.000 title description 28
238000004519 manufacturing process Methods 0.000 title 1
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 109
229910052751 metal Inorganic materials 0.000 description 76
239000002184 metal Substances 0.000 description 76
229960004679 doxorubicin Drugs 0.000 description 51
229930182470 glycoside Natural products 0.000 description 47
150000002338 glycosides Chemical class 0.000 description 47
150000001875 compounds Chemical class 0.000 description 34
150000001768 cations Chemical class 0.000 description 23
238000000034 method Methods 0.000 description 23
239000003446 ligand Substances 0.000 description 19
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 18
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 16
XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 16
229960000975 daunorubicin Drugs 0.000 description 14
206010048610 Cardiotoxicity Diseases 0.000 description 12
231100000259 cardiotoxicity Toxicity 0.000 description 12
108091006112 ATPases Proteins 0.000 description 10
102000057290 Adenosine Triphosphatases Human genes 0.000 description 10
238000002474 experimental method Methods 0.000 description 10
239000000243 solution Substances 0.000 description 10
239000010949 copper Substances 0.000 description 9
206010028980 Neoplasm Diseases 0.000 description 8
150000002739 metals Chemical class 0.000 description 8
229910003251 Na K Inorganic materials 0.000 description 7
239000011575 calcium Substances 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
241000699670 Mus sp. Species 0.000 description 6
230000003115 biocidal effect Effects 0.000 description 6
201000011510 cancer Diseases 0.000 description 6
230000000694 effects Effects 0.000 description 6
230000000174 oncolytic effect Effects 0.000 description 6
239000000376 reactant Substances 0.000 description 6
VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 5
239000003242 anti bacterial agent Substances 0.000 description 5
229940088710 antibiotic agent Drugs 0.000 description 5
239000013522 chelant Substances 0.000 description 5
230000009920 chelation Effects 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
229910052742 iron Inorganic materials 0.000 description 5
208000032839 leukemia Diseases 0.000 description 5
230000008569 process Effects 0.000 description 5
231100000419 toxicity Toxicity 0.000 description 5
230000001988 toxicity Effects 0.000 description 5
238000011282 treatment Methods 0.000 description 5
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
230000006820 DNA synthesis Effects 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
229910052791 calcium Inorganic materials 0.000 description 4
230000008859 change Effects 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
230000001079 digestive effect Effects 0.000 description 4
238000010494 dissociation reaction Methods 0.000 description 4
230000005593 dissociations Effects 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
229910021578 Iron(III) chloride Inorganic materials 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
229940009456 adriamycin Drugs 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000006227 byproduct Substances 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000008014 freezing Effects 0.000 description 3
238000007710 freezing Methods 0.000 description 3
231100000226 haematotoxicity Toxicity 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
230000003993 interaction Effects 0.000 description 3
RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 3
230000035699 permeability Effects 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000007858 starting material Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
HJEZFVLKJYFNQW-PRFXOSGESA-N (13S)-13-dihydrodaunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)[C@H](C)O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 HJEZFVLKJYFNQW-PRFXOSGESA-N 0.000 description 2
TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 2
PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 2
HJEZFVLKJYFNQW-UHFFFAOYSA-N Daunorubicinol Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)O)CC1OC1CC(N)C(O)C(C)O1 HJEZFVLKJYFNQW-UHFFFAOYSA-N 0.000 description 2
OWCHPBVMSHIYCQ-UHFFFAOYSA-N Dihydro-dauno-mycinon Natural products C1C(O)(C(C)O)CC(O)C2=C1C(O)=C1C(=O)C(C=CC=C3OC)=C3C(=O)C1=C2O OWCHPBVMSHIYCQ-UHFFFAOYSA-N 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
ZJBMQVPEJHVSQA-UHFFFAOYSA-N Rutilantin Natural products C12=C(O)C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C=C2C(C(=O)OC)C(CC)(O)CC1OC1CC(N(C)C)C(O)C(C)O1 ZJBMQVPEJHVSQA-UHFFFAOYSA-N 0.000 description 2
230000009102 absorption Effects 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
230000009471 action Effects 0.000 description 2
229940100198 alkylating agent Drugs 0.000 description 2
239000002168 alkylating agent Substances 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
206010003119 arrhythmia Diseases 0.000 description 2
230000006793 arrhythmia Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
230000007681 cardiovascular toxicity Effects 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
229910017052 cobalt Inorganic materials 0.000 description 2
239000010941 cobalt Substances 0.000 description 2
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
230000001186 cumulative effect Effects 0.000 description 2
229950000950 daunorubicinol Drugs 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
235000011389 fruit/vegetable juice Nutrition 0.000 description 2
125000003563 glycoside group Chemical group 0.000 description 2
230000002489 hematologic effect Effects 0.000 description 2
PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
231100001231 less toxic Toxicity 0.000 description 2
231100000053 low toxicity Toxicity 0.000 description 2
239000000463 material Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000001613 neoplastic effect Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
238000003756 stirring Methods 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
229960000641 zorubicin Drugs 0.000 description 2
WTJXVDPDEQKTCV-VQAITOIOSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O WTJXVDPDEQKTCV-VQAITOIOSA-N 0.000 description 1
NWPIUETWDSWOKV-ZUOHIMJMSA-N (7s,9r,10r)-7,10-bis[[(2s,4s,5s,6s)-4-(dimethylamino)-5-hydroxy-6-methyloxan-2-yl]oxy]-9-ethyl-4,6,9,11-tetrahydroxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound O([C@H]1C[C@]([C@@H](C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)O[C@@H]1O[C@@H](C)[C@@H](O)[C@H](C1)N(C)C)(O)CC)[C@H]1C[C@H](N(C)C)[C@H](O)[C@H](C)O1 NWPIUETWDSWOKV-ZUOHIMJMSA-N 0.000 description 1
YOFDHOWPGULAQF-MQJDWESPSA-N (7s,9s)-9-acetyl-6,7,9,11-tetrahydroxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound C1[C@@](O)(C(C)=O)C[C@H](O)C2=C1C(O)=C1C(=O)C(C=CC=C3OC)=C3C(=O)C1=C2O YOFDHOWPGULAQF-MQJDWESPSA-N 0.000 description 1
PHJGQLKATGFLAB-UHFFFAOYSA-N 1,2,3,4-tetrahydrotetracene Chemical compound C1=CC=C2C=C(C=C3C(CCCC3)=C3)C3=CC2=C1 PHJGQLKATGFLAB-UHFFFAOYSA-N 0.000 description 1
OEPOKWHJYJXUGD-UHFFFAOYSA-N 2-(3-phenylmethoxyphenyl)-1,3-thiazole-4-carbaldehyde Chemical compound O=CC1=CSC(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 OEPOKWHJYJXUGD-UHFFFAOYSA-N 0.000 description 1
KCOULPRVOZDQEL-IFNZWHIZSA-N Aquayamycin Chemical compound C1[C@@H](O)[C@H](O)[C@@H](C)O[C@H]1C1=CC=C(C(=O)C=2[C@]3(C(=O)C[C@](C)(O)C[C@@]3(O)C=CC=2C2=O)O)C2=C1O KCOULPRVOZDQEL-IFNZWHIZSA-N 0.000 description 1
KCOULPRVOZDQEL-UHFFFAOYSA-N Aquayamycin Natural products C1C(O)C(O)C(C)OC1C1=CC=C(C(=O)C=2C3(C(=O)CC(C)(O)CC3(O)C=CC=2C2=O)O)C2=C1O KCOULPRVOZDQEL-UHFFFAOYSA-N 0.000 description 1
ZBDDFHXUDIPRSM-UHFFFAOYSA-N Cinerubin-B Natural products O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(O)=C1C(OC3OC(C)C(OC4OC(C)C5OC6OC(C)C(=O)CC6OC5C4)C(C3)N(C)C)CC(CC)(O)C(C(=O)OC)C1=C2 ZBDDFHXUDIPRSM-UHFFFAOYSA-N 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
YOFDHOWPGULAQF-UHFFFAOYSA-N Daunomycin-Aglycone Natural products C1C(O)(C(C)=O)CC(O)C2=C1C(O)=C1C(=O)C(C=CC=C3OC)=C3C(=O)C1=C2O YOFDHOWPGULAQF-UHFFFAOYSA-N 0.000 description 1
NKZRZOVSJNSBFR-UHFFFAOYSA-N Doxorubicinol Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(O)CO)CC1OC1CC(N)C(O)C(C)O1 NKZRZOVSJNSBFR-UHFFFAOYSA-N 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
CTKINSOISVBQLD-UHFFFAOYSA-N Glycidol Chemical compound OCC1CO1 CTKINSOISVBQLD-UHFFFAOYSA-N 0.000 description 1
ZWVCTHFFGBPZIN-UHFFFAOYSA-N Isorhodomycin-A Natural products C12=C(O)C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C2C(OC2OC(C)C(O)C(C2)N(C)C)C(CC)(O)CC1OC1CC(N(C)C)C(O)C(C)O1 ZWVCTHFFGBPZIN-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
102000003939 Membrane transport proteins Human genes 0.000 description 1
108090000301 Membrane transport proteins Proteins 0.000 description 1
-1 Mn (II) Chemical class 0.000 description 1
CLLLLOXMTHXCIT-PEJRKRSVSA-N N-[(E)-1-[(2S,4S)-4-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethylideneamino]-4-(dimethylamino)benzamide hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC(=CC=1)N(C)C)C1CC(N)C(O)C(C)O1 CLLLLOXMTHXCIT-PEJRKRSVSA-N 0.000 description 1
VTIPCNDIYJAFJJ-JRRDRPCMSA-N N-[(E)-1-[(2S,4S)-4-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethylideneamino]pentanamide hydrochloride Chemical compound Cl.O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(/C)=N/NC(=O)CCCC)C1CC(N)C(O)C(C)O1 VTIPCNDIYJAFJJ-JRRDRPCMSA-N 0.000 description 1
ZJBMQVPEJHVSQA-OCYVVMCSSA-N Pyrromycin Chemical compound O([C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)[C@H]1C[C@H](N(C)C)[C@H](O)[C@H](C)O1 ZJBMQVPEJHVSQA-OCYVVMCSSA-N 0.000 description 1
NWPIUETWDSWOKV-UHFFFAOYSA-N Rhodomycin A Natural products C12=C(O)C=3C(=O)C4=C(O)C=CC=C4C(=O)C=3C(O)=C2C(OC2OC(C)C(O)C(C2)N(C)C)C(CC)(O)CC1OC1CC(N(C)C)C(O)C(C)O1 NWPIUETWDSWOKV-UHFFFAOYSA-N 0.000 description 1
HINUXGZHCXYZMB-UHFFFAOYSA-N Rhodomycin B Natural products C12=C(O)C=3C(=O)C4=C(O)C=CC=C4C(=O)C=3C(O)=C2C(O)C(CC)(O)CC1OC1CC(N(C)C)C(O)C(C)O1 HINUXGZHCXYZMB-UHFFFAOYSA-N 0.000 description 1
PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
LJZPVWKMAYDYAS-QKKPTTNWSA-N aclacinomycin T Chemical compound O([C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)[C@H]1C[C@H](N(C)C)[C@H](O)[C@H](C)O1 LJZPVWKMAYDYAS-QKKPTTNWSA-N 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
HINUXGZHCXYZMB-DJNFHWKQSA-N beta-Rhodomycin Chemical compound O([C@H]1C[C@]([C@@H](C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)O)(O)CC)[C@H]1C[C@H](N(C)C)[C@H](O)[C@H](C)O1 HINUXGZHCXYZMB-DJNFHWKQSA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
230000036471 bradycardia Effects 0.000 description 1
208000006218 bradycardia Diseases 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
231100000457 cardiotoxic Toxicity 0.000 description 1
230000001451 cardiotoxic effect Effects 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
STUJMJDONFVTGM-UHFFFAOYSA-N cinerubine A Natural products C12=C(O)C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C=C2C(C(=O)OC)C(CC)(O)CC1OC(OC1C)CC(N(C)C)C1OC(OC1C)CC(O)C1OC1CCC(=O)C(C)O1 STUJMJDONFVTGM-UHFFFAOYSA-N 0.000 description 1
238000000576 coating method Methods 0.000 description 1
GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
WPJRFCZKZXBUNI-HCWXCVPCSA-N daunosamine Chemical group C[C@H](O)[C@@H](O)[C@@H](N)CC=O WPJRFCZKZXBUNI-HCWXCVPCSA-N 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
125000004989 dicarbonyl group Chemical group 0.000 description 1
RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical group OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
NKZRZOVSJNSBFR-FEMMEMONSA-N doxorubicinol Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)[C@@H](O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 NKZRZOVSJNSBFR-FEMMEMONSA-N 0.000 description 1
229960004887 ferric hydroxide Drugs 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
150000004679 hydroxides Chemical class 0.000 description 1
208000006278 hypochromic anemia Diseases 0.000 description 1
238000007654 immersion Methods 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
210000005027 intestinal barrier Anatomy 0.000 description 1
230000007358 intestinal barrier function Effects 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
IEECXTSVVFWGSE-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide Chemical compound [OH-].[O-2].[Fe+3] IEECXTSVVFWGSE-UHFFFAOYSA-M 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000009061 membrane transport Effects 0.000 description 1
150000002736 metal compounds Chemical class 0.000 description 1
ZBDDFHXUDIPRSM-DQCCILMQSA-N methyl (1r,2r,4s)-4-[(2r,4s,5s,6s)-5-[[(2s,4as,5as,7s,9s,9ar,10ar)-2,9-dimethyl-3-oxo-4,4a,5a,6,7,9,9a,10a-octahydrodipyrano[4,2-a:4',3'-e][1,4]dioxin-7-yl]oxy]-4-(dimethylamino)-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7,10-tetrahydroxy-6,11-dioxo-3,4-dihydro-1 Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(O)=C1[C@@H](O[C@@H]3O[C@@H](C)[C@@H](O[C@@H]4O[C@@H](C)[C@H]5O[C@@H]6O[C@@H](C)C(=O)C[C@@H]6O[C@H]5C4)[C@H](C3)N(C)C)C[C@@](CC)(O)[C@H](C(=O)OC)C1=C2 ZBDDFHXUDIPRSM-DQCCILMQSA-N 0.000 description 1
STUJMJDONFVTGM-CEPMKHARSA-N methyl (1r,2r,4s)-4-[4-(dimethylamino)-5-[4-hydroxy-6-methyl-5-(6-methyl-5-oxooxan-2-yl)oxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7,10-tetrahydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylate Chemical compound O([C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)C(OC1C)CC(N(C)C)C1OC(OC1C)CC(O)C1OC1CCC(=O)C(C)O1 STUJMJDONFVTGM-CEPMKHARSA-N 0.000 description 1
RWAWIXIPEZJLIU-PQTMXZPYSA-N methyl (2s,4s)-4-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracene-2-carboxylate;hydrochloride Chemical compound Cl.O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)OC)C1CC(N)C(O)C(C)O1 RWAWIXIPEZJLIU-PQTMXZPYSA-N 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
OEXFGUZYSWDUME-IKIAVLLTSA-N n-[(e)-1-[(2s,4s)-4-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]ethylideneamino]-3,4-dichlorobenzamide;hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=C(Cl)C(Cl)=CC=1)C1CC(N)C(O)C(C)O1 OEXFGUZYSWDUME-IKIAVLLTSA-N 0.000 description 1
QEORIOWOGNHTED-YMYQXXOFSA-N n-[(e)-1-[(2s,4s)-4-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]ethylideneamino]-3-nitrobenzamide;hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=C(C=CC=1)[N+]([O-])=O)C1CC(N)C(O)C(C)O1 QEORIOWOGNHTED-YMYQXXOFSA-N 0.000 description 1
XODZATMXRHPIHP-AHJJWDLHSA-N n-[(e)-1-[(2s,4s)-4-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]ethylideneamino]-4-butoxybenzamide;hydrochloride Chemical compound Cl.C1=CC(OCCCC)=CC=C1C(=O)N\N=C(/C)[C@]1(O)CC2=C(O)C(C(=O)C3=CC=CC(OC)=C3C3=O)=C3C(O)=C2[C@@H](OC2OC(C)C(O)C(N)C2)C1 XODZATMXRHPIHP-AHJJWDLHSA-N 0.000 description 1
TWPKQOAFJZUCMV-FYBMHLGZSA-N n-[(e)-1-[(2s,4s)-4-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]ethylideneamino]-4-chlorobenzamide;hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC(Cl)=CC=1)C1CC(N)C(O)C(C)O1 TWPKQOAFJZUCMV-FYBMHLGZSA-N 0.000 description 1
DJJMHKWTEUINSV-PEJRKRSVSA-N n-[(e)-1-[(2s,4s)-4-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]ethylideneamino]-4-ethylbenzamide;hydrochloride Chemical compound Cl.C1=CC(CC)=CC=C1C(=O)N\N=C(/C)[C@]1(O)CC2=C(O)C(C(=O)C3=CC=CC(OC)=C3C3=O)=C3C(O)=C2[C@@H](OC2OC(C)C(O)C(N)C2)C1 DJJMHKWTEUINSV-PEJRKRSVSA-N 0.000 description 1
MOSSFAKZPSXVDK-YMYQXXOFSA-N n-[(e)-1-[(2s,4s)-4-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]ethylideneamino]-4-hydroxybenzamide;hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC(O)=CC=1)C1CC(N)C(O)C(C)O1 MOSSFAKZPSXVDK-YMYQXXOFSA-N 0.000 description 1
XPJNALLKSPIRLR-BJGBBBQGSA-N n-[(e)-1-[(2s,4s)-4-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]ethylideneamino]-4-methoxybenzamide;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1C(=O)N\N=C(/C)[C@]1(O)CC2=C(O)C(C(=O)C3=CC=CC(OC)=C3C3=O)=C3C(O)=C2[C@@H](OC2OC(C)C(O)C(N)C2)C1 XPJNALLKSPIRLR-BJGBBBQGSA-N 0.000 description 1
HXGOMIWIDNPPPN-CYDQPGSWSA-N n-[(e)-1-[(2s,4s)-4-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]ethylideneamino]-4-phenylbenzamide;hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC(=CC=1)C=1C=CC=CC=1)C1CC(N)C(O)C(C)O1 HXGOMIWIDNPPPN-CYDQPGSWSA-N 0.000 description 1
NKFHKYQGZDAKMX-PPRKPIOESA-N n-[(e)-1-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]ethylideneamino]benzamide;hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 NKFHKYQGZDAKMX-PPRKPIOESA-N 0.000 description 1
DFODJOCFAAIAJF-YYFOJOLUSA-N n-[(e)-[1-[(2s,4s)-4-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-hydroxyethylidene]amino]-3,4-dichlorobenzamide;hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\CO)=N\NC(=O)C=1C=C(Cl)C(Cl)=CC=1)C1CC(N)C(O)C(C)O1 DFODJOCFAAIAJF-YYFOJOLUSA-N 0.000 description 1
URAAKUHYAZJPFM-ZMVHGRJNSA-N n-[(e)-[1-[(2s,4s)-4-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-hydroxyethylidene]amino]benzamide;hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\CO)=N\NC(=O)C=1C=CC=CC=1)C1CC(N)C(O)C(C)O1 URAAKUHYAZJPFM-ZMVHGRJNSA-N 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
150000002823 nitrates Chemical class 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
KGTDRFCXGRULNK-JYOBTZKQSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](OC)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@@]5(C)O[C@H]([C@H]([C@@H]([C@H]5O)N(C)C)O)OC4=C3C3=O)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 KGTDRFCXGRULNK-JYOBTZKQSA-N 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000008635 plant growth Effects 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000002689 soil Substances 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
229910021655 trace metal ion Inorganic materials 0.000 description 1
238000002834 transmittance Methods 0.000 description 1
230000032258 transport Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
238000002211 ultraviolet spectrum Methods 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
238000001429 visible spectrum Methods 0.000 description 1
FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Biotechnology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

CH48477A 1976-01-16 1977-01-14 Verfahren zur herstellung von neuen anthracyclinglycosid-derivaten. CH629219A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
ES444380A ES444380A1 (es)	1976-01-16	1976-01-16	Un procedimiento para preparar derivados metalicos antraci- clinicos.

Publications (1)

Publication Number	Publication Date
CH629219A5 true CH629219A5 (de)	1982-04-15

Family

ID=8470743

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CH48477A CH629219A5 (de)	1976-01-16	1977-01-14	Verfahren zur herstellung von neuen anthracyclinglycosid-derivaten.

Country Status (29)

Country	Link
US (1)	US4138480A (2)
JP (1)	JPS52111555A (2)
AR (1)	AR218620A1 (2)
AT (1)	AT349634B (2)
AU (1)	AU513698B2 (2)
BE (1)	BE850438A (2)
CA (1)	CA1070680A (2)
CH (1)	CH629219A5 (2)
DD (1)	DD129452A5 (2)
DE (1)	DE2701405C2 (2)
DK (1)	DK11877A (2)
EG (1)	EG12735A (2)
ES (1)	ES444380A1 (2)
FI (1)	FI770115A7 (2)
FR (1)	FR2338285A1 (2)
GB (1)	GB1568263A (2)
GR (1)	GR70696B (2)
HU (1)	HU177832B (2)
IE (1)	IE44689B1 (2)
IL (1)	IL51264A (2)
NL (1)	NL7700379A (2)
NO (1)	NO770122L (2)
NZ (1)	NZ183084A (2)
PH (1)	PH16582A (2)
PL (1)	PL108660B1 (2)
PT (1)	PT66067B (2)
SE (1)	SE7700398L (2)
SU (1)	SU886748A3 (2)
YU (1)	YU5477A (2)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2959798A (en) *	1958-03-24	1960-11-15	Champlin Oil & Refining Co	Pipe line cleaner
US4337335A (en) *	1978-05-18	1982-06-29	Schering Corporation	Transition metal salt complexes of polyamino organic compounds
IT1184161B (it) *	1985-03-14	1987-10-22	Franco Conti	Derivati del chitosano costituiti da complessi di coordinazione con ioni ferrosi
JPS63310830A (ja) *	1987-06-10	1988-12-19	Meiji Seika Kaisha Ltd	抗レトロウイルス剤
GB9613182D0 (en) *	1996-06-24	1996-08-28	Nycomed Imaging As	Method
NL1009226C2 (nl) *	1998-05-20	1999-11-24	Faculteit Geneeskunde Universi	Toepassing van een nucleïnezuur-bindend chemotherapeutisch agens, een farmaceutisch preparaat en een geneesmiddelcombinatie.
US20060198882A1 (en) *	2003-03-21	2006-09-07	Yechezkel Barenholz	Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer
US7053191B2 (en) *	2003-05-21	2006-05-30	Solux Corporation	Method of preparing 4-R-substituted 4-demethoxydaunorubicin
EP1817004A2 (en) *	2004-11-15	2007-08-15	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Combination therapy associating preferably a ceramide with a cytotoxic drug
WO2008100591A2 (en) *	2007-02-14	2008-08-21	The General Hospital Corporation	Modulation of nitric oxide signaling to normalize tumor vasculature
DK3327148T3 (da)	2010-06-18	2021-04-12	Myriad Genetics Inc	Fremgangsmåder til forudsigelse af status for brca1- og brca2-gener i en cancercelle
ES2704303T3 (es)	2010-08-24	2019-03-15	Dana Farber Cancer Inst Inc	Procedimientos para la predicción de una respuesta contra el cáncer
EP4563709A3 (en)	2011-06-17	2025-09-03	Myriad Genetics, Inc.	Methods and materials for assessing allelic imbalance
CN107267598B (zh)	2011-12-21	2022-03-25	美瑞德生物工程公司	用于评估杂合性丢失的方法与材料
WO2013130347A1 (en)	2012-02-23	2013-09-06	The Children's Hospital Corporation	Methods for predicting anti-cancer response
ES2658867T3 (es)	2012-06-07	2018-03-12	Institut Curie	Métodos para detectar la inactivación de la ruta de recombinación homóloga (BRCA1/2) en tumores humanos
WO2014160080A1 (en)	2013-03-14	2014-10-02	Children's Medical Center Corporation	Cancer diagnosis, treatment selection and treatment
DK2981624T3 (da)	2013-04-05	2020-03-02	Myriad Genetics Inc	Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling
EP3080292B1 (en)	2013-12-09	2022-02-02	Institut Curie	Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
EP4234711B1 (en)	2014-08-15	2025-05-28	Myriad Genetics, Inc.	Methods and materials for assessing homologous recombination deficiency
EP4141127B1 (en)	2021-08-30	2024-10-09	Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln	Method for assessing homologous recombination deficiency in ovarian cancer cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3074927A (en) *	1960-04-12	1963-01-22	Paul D Saltman	Metallic complexes of reducing sugars
YU33730B (en) *	1967-04-18	1978-02-28	Farmaceutici Italia	Process for preparing a novel antibiotic substance and salts thereof
GB1469430A (en) *	1974-12-24	1977-04-06	Farmaceutici Italia	Daunomycin derivatives

1976
- 1976-01-16 ES ES444380A patent/ES444380A1/es not_active Expired
1977
- 1977-01-08 EG EG12/77A patent/EG12735A/xx active
- 1977-01-11 HU HU77GO1361A patent/HU177832B/hu unknown
- 1977-01-11 US US05/758,446 patent/US4138480A/en not_active Expired - Lifetime
- 1977-01-12 AR AR266173A patent/AR218620A1/es active
- 1977-01-13 PT PT66067A patent/PT66067B/pt unknown
- 1977-01-13 DK DK11877A patent/DK11877A/da not_active Application Discontinuation
- 1977-01-13 AU AU21319/77A patent/AU513698B2/en not_active Expired
- 1977-01-14 NO NO770122A patent/NO770122L/no unknown
- 1977-01-14 DE DE2701405A patent/DE2701405C2/de not_active Expired
- 1977-01-14 JP JP252277A patent/JPS52111555A/ja active Granted
- 1977-01-14 SE SE7700398A patent/SE7700398L/xx unknown
- 1977-01-14 PH PH19347A patent/PH16582A/en unknown
- 1977-01-14 CH CH48477A patent/CH629219A5/de not_active IP Right Cessation
- 1977-01-14 AT AT19677A patent/AT349634B/de not_active IP Right Cessation
- 1977-01-14 NZ NZ183084A patent/NZ183084A/xx unknown
- 1977-01-14 SU SU772439103A patent/SU886748A3/ru active
- 1977-01-14 NL NL7700379A patent/NL7700379A/xx not_active Application Discontinuation
- 1977-01-14 FI FI770115A patent/FI770115A7/fi not_active Application Discontinuation
- 1977-01-14 CA CA269,807A patent/CA1070680A/en not_active Expired
- 1977-01-14 IL IL51264A patent/IL51264A/xx unknown
- 1977-01-14 FR FR7701034A patent/FR2338285A1/fr active Granted
- 1977-01-15 GR GR52580A patent/GR70696B/el unknown
- 1977-01-15 PL PL1977195344A patent/PL108660B1/pl not_active IP Right Cessation
- 1977-01-17 DD DD7700196969A patent/DD129452A5/xx unknown
- 1977-01-17 GB GB2367/77A patent/GB1568263A/en not_active Expired
- 1977-01-17 IE IE87/77A patent/IE44689B1/en unknown
- 1977-01-17 BE BE174119A patent/BE850438A/xx not_active IP Right Cessation
- 1977-03-21 YU YU00054/77A patent/YU5477A/xx unknown

Also Published As

Publication number	Publication date
CA1070680A (en)	1980-01-29
PT66067B (en)	1978-06-23
JPS52111555A (en)	1977-09-19
PL195344A1 (pl)	1978-08-14
ES444380A1 (es)	1977-06-16
FR2338285B1 (2)	1980-03-14
IL51264A (en)	1980-05-30
SE7700398L (sv)	1977-07-17
IE44689B1 (en)	1982-02-24
HU177832B (en)	1981-12-28
NL7700379A (nl)	1977-07-19
IE44689L (en)	1977-07-16
PL108660B1 (en)	1980-04-30
AT349634B (de)	1979-04-10
DK11877A (da)	1977-07-17
BE850438A (fr)	1977-05-16
GB1568263A (en)	1980-05-29
AU2131977A (en)	1978-07-20
US4138480A (en)	1979-02-06
YU5477A (en)	1982-06-30
DE2701405C2 (de)	1986-02-27
PT66067A (en)	1977-02-01
FR2338285A1 (fr)	1977-08-12
AU513698B2 (en)	1980-12-18
DE2701405A1 (de)	1977-07-21
EG12735A (en)	1981-03-31
JPS6133039B2 (2)	1986-07-31
GR70696B (2)	1982-12-30
ATA19677A (de)	1978-09-15
NO770122L (no)	1977-07-19
DD129452A5 (de)	1978-01-18
PH16582A (en)	1983-11-22
SU886748A3 (ru)	1981-11-30
IL51264A0 (en)	1977-03-31
FI770115A7 (2)	1977-07-17
AR218620A1 (es)	1980-06-30
NZ183084A (en)	1980-04-28

Legal Events

Date	Code	Title	Description
1989-09-29	PL	Patent ceased
2024-10-31	PL	Patent ceased

Publication	Publication Date	Title
CH629219A5 (de)	1982-04-15	Verfahren zur herstellung von neuen anthracyclinglycosid-derivaten.
DE3586759T2 (de)	1993-03-04	Antitumor-platin-komplexe.
DE2845373C2 (2)	1991-06-13
DE3152175C2 (2)	1989-11-30
DE2845372C2 (2)	1990-12-13
DE69621521T2 (de)	2003-01-02	Cyclodextrinderivate, ihre Herstellung und Verwendung zur Einbringung von hydrophoben Molekülen in strukturierten Tensidsystemen
DE2359333A1 (de)	1974-06-12	Verfahren zur herstellung eines dopapraeparats
DE2751395C2 (de)	1982-10-28	Anthracyclindisaccharide und deren Verwendung
DE2310462B2 (de)	1975-01-09	Phleomycine und Verfahren zu ihrer Herstellung
DE2828933B2 (2)	1980-01-10
DE1293144B (de)	1969-04-24	Verfahren zur Herstellung von Komplexverbindungen des Eisens mit Sorbit, Gluconsaeure und einem Oligosaccharid
DE3026425C2 (2)	1989-11-09
DE3515178A1 (de)	1985-11-28	Verfahren zur herstellung von neuen anthracyclinkonjugaten anionischer polymerer
EP1401425A1 (de)	2004-03-31	Metallorganisches antitumormittel
DE3207021A1 (de)	1982-09-23	Aminoacridin-(alpha)- und/oder (beta)-(d)-n-glykosid- und/oder aminoacridin-(alpha)- und/oder (beta)-(l)-n-glykosidderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE602004006153T2 (de)	2007-12-27	KRISTALLINE VERBINDUNG VON 4'-DEMETHYL-4'-PHOSPHAT-2'',3''-BISPENTAFLUORPHENOXYiACETYL-4'',6''-ETHYLIDEN-ß-D-EPIPODOiPHYLLOTOXINiGLUKOSID ENTWEDER IN DER FREIEN FORM ODER SOLVATISIERT MIT ETHANOL
DE2519757C3 (2)	1978-04-06
DE2738656C2 (2)	1989-08-31
CH641454A5 (de)	1984-02-29	Cyclische acetale, verfahren zu ihrer herstellung und arzneimittel.
DE2932968C2 (2)	1989-03-16
DE60003328T2 (de)	2004-04-29	Ruthenium (ii) komplexe mit hoher antitumor und antimetastatischer wirkung
DE2307976B2 (de)	1979-12-06	3-Aminopropylester der Bleomycinsäure, Verfahren zu dessen Herstellung und Verfahren zur Herstellung von Bleomycinsäure
DE10201693A1 (de)	2003-01-16	Metallorganisches Antitumormittel
AT325783B (de)	1975-11-10	Verfahren zum abtrennen des glykofrangulin-komplexes aus pflanzlichen rohstoffen, insbesondere aus der getrockneten rinde des faulbaumes
DE1809875A1 (de)	1969-07-03	Neue Enduracidinderivate und Verfahren zu ihrer Herstellung